Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Dermatol ; 176(3): 577-593, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27273146

ABSTRACT

Planners of interventional studies in psoriasis face the dilemma of selecting suitable quality-of-life (QoL) measures. Systematic reviews have the potential of identifying psychometrically sound measures in a given therapeutic area, while guiding the development of practice guidelines. The aim of this systematic review was to generate evidence of the use of QoL instruments in randomized controlled trials (RCTs) for interventions in psoriasis. The methodology followed the PRISMA guidelines. Six databases were searched with 388 search terms. Abstracts of articles were reviewed independently by two assessors, and a third adjudicator resolved any opinion differences. Risk of bias was assessed using the Jadad scale. Of 3646 screened publications, 99 articles (100 trials) met the eligibility criteria for inclusion, describing research on 33 215 patients. Thirty-three trials tested topical therapy, 18 systemic, 39 biologics, nine phototherapy and 10 other interventions. The Dermatology Life Quality Index (DLQI) was the most commonly used QoL instrument (83 studies, 83%), followed by the 36-Item Short Form Survey (SF-36) (31, 31%), EuroQoL-5D (EQ-5D) (15, 15%), Psoriasis Disability Index (14, 14%) and Skindex (five, 5%). There was widespread inconsistency in the way that QoL data were reported. Of the 100 trials identified, 37 reported minimal clinically important difference (MCID): 32 for DLQI, 10 for SF-36 and six for EQ-5D. QoL measurement is increasingly being reported in RCTs of psoriasis. Formal guidelines are needed for assessment and publishing of QoL data. Researchers should consider whether MCID information is available, and development of MCID data should be encouraged.


Subject(s)
Psoriasis/therapy , Quality of Life , Randomized Controlled Trials as Topic/methods , Humans , Practice Guidelines as Topic , Severity of Illness Index , Surveys and Questionnaires , Treatment Outcome
2.
J Eur Acad Dermatol Venereol ; 26(11): 1360-3, 2012 Nov.
Article in English | MEDLINE | ID: mdl-21967654

ABSTRACT

BACKGROUND: Nevus of Ota is a rare pigmentary disorder characterized by melanocytic hamartoma of the skin along the distribution of trigeminal nerve branches. AIM: To study the morphological features of nevus of Ota, and their relation with facial regions and trigeminal branches areas. METHODS: Patients with nevus of Ota who attended Kuwait University Hospital dermatology clinic and a private dermatology clinic in Sana'a, Yemen, between January 2008 and December 2010, were clinically evaluated. The morphology of nevus of Ota was classified to homogenous, speckled or mixed. The distribution of the lesions was assessed based on both facial regions and areas supplied by the trigeminal nerve. RESULTS: Forty-seven patients with nevus of Ota (F = 38, M = 9) were evaluated. Eighty percent of patients were females. Mixed (homogenous and speckled) appearance was seen in 47% of all patients. Periocular region was the most commonly affected facial region (67%), and the maxillary area was the most commonly involved trigeminal branch area (94%). Forty-seven percent of cases had scleral pigmentation. Interesting features of nevus of Ota involving the nasal septum and crossing the midline of the face were noted. CONCLUSIONS: To the best of our knowledge, this is the first study that examines the distribution and morphology of nevus of Ota in Middle Eastern population. Including the morphological appearance of the nevus is practical and more clinically descriptive, and therefore should be integrated in the classification in future studies.


Subject(s)
Nevus of Ota/pathology , Female , Humans , Male , Nevus of Ota/epidemiology , Yemen/epidemiology
3.
J Eur Acad Dermatol Venereol ; 24(7): 747-55, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20015176

ABSTRACT

Sarcoidosis is a multiorgan granulomatous disease in which the skin is one of the frequently involved target organs. Cutaneous involvement occurs in a third of patients with sarcoidosis and has protean manifestations. More than a century has passed since the initial description of sarcoidosis, but its cause continues to be an enigma. Recent studies have introduced several new insights into the pathogenesis of this disease. The aim of this literature review was to provide a comprehensive overview on the current updates in the pathogenesis of sarcoidosis. This review has revealed that several genetic polymorphisms are associated with an increased risk of developing sarcoidosis, suggesting that genetic susceptibility to sarcoidosis is probably polygenic. Environmental factors may also modify the susceptibility to sarcoidosis. Evidence favouring an infectious aetiology has been accumulating, but the results of studies are conflicting. The current concept is that the pathogenesis of sarcoidosis involves a T-helper-1-mediated immune response to environmental antigens in a genetically susceptible host. The studies carried out on sarcoidosis have largely focused on the pulmonary aspects and have been mainly conducted by respiratory physicians. In contrast, research conducted on the cutaneous aspects of sarcoidosis is comparatively limited. Although tremendous advances have been made, there is a significant gap between the vast knowledge accumulated on sarcoidosis in recent years and the understanding of this disease.


Subject(s)
Sarcoidosis/pathology , Skin Diseases/pathology , Environmental Exposure , Genetic Predisposition to Disease , Humans , Polymorphism, Genetic , Sarcoidosis/etiology , Sarcoidosis/genetics , Skin Diseases/etiology , Skin Diseases/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...